EcoDrugPlus

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSSTOG00000010404
Gene Symbol: FRK
3 Cross references
216 Possible Orthologues:

Galactosidase Alpha

Ensembl ID : ENSSTOG00000004771
Gene Symbol: GLA
4 Cross references
196 Possible Orthologues:

Galectin 1

Ensembl ID : ENSSTOG00000003912
Gene Symbol: LGALS1
3 Cross references
380 Possible Orthologues:

Galectin 3

Ensembl ID : ENSSTOG00000026024
Gene Symbol: LGALS3
4 Cross references
218 Possible Orthologues:

Gamma-Aminobutyric Acid Receptor Subunit Pi Pseudogene

Ensembl ID : ENSSTOG00000023441
Gene Symbol: LOC101966805
1 Cross references
123 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Pi Subunit

Ensembl ID : ENSSTOG00000014692
Gene Symbol: GABRP
2 Cross references
123 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha1

Ensembl ID : ENSSTOG00000023032
Gene Symbol: GABRA1
3 Cross references
202 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha2

Ensembl ID : ENSSTOG00000004767
Gene Symbol: GABRA2
3 Cross references
253 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha3

Ensembl ID : ENSSTOG00000004338
Gene Symbol: GABRA3
3 Cross references
198 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha4

Ensembl ID : ENSSTOG00000001951
Gene Symbol: GABRA4
4 Cross references
201 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha5

Ensembl ID : ENSSTOG00000014502
Gene Symbol: GABRA5
3 Cross references
262 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha6

Ensembl ID : ENSSTOG00000024430
Gene Symbol: GABRA6
3 Cross references
195 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).